What is Polyneuron Pharmaceuticals?
Polyneuron Pharmaceuticals is a pioneering biotechnology firm specializing in the precision treatment of antibody-mediated autoimmune diseases. Originating as a spin-off from the University of Basel in 2014, the company has developed the innovative Antibody-Catch technology platform. This proprietary system utilizes biodegradable injectable glycopolymers designed to selectively neutralize pathological autoantibodies while maintaining the integrity of the broader immune system. The company's lead candidate, PN-1007, is currently undergoing Phase I clinical evaluation, representing a significant milestone in the firm's mission to provide targeted, life-changing therapies for patients suffering from severe autoimmune conditions.
How much funding has Polyneuron Pharmaceuticals raised?
Polyneuron Pharmaceuticals has raised a total of $43M across 2 funding rounds:
Angel/Seed
$3.1M
Series A
$39.9M
Angel/Seed (2016): $3.1M with participation from Zorcher Kantonalbank and EVA Basel
Series A (2020): $39.9M led by Sofinnova Partners, HBM Healthcare Investments, and New Enterprise Associates
Key Investors in Polyneuron Pharmaceuticals
Sofinnova Partners
A leading European venture capital firm in life sciences, specializing in healthcare and sustainability with a hands-on approach to company building.
HBM Healthcare Investments
A publicly traded investment firm focused on the global healthcare sector, targeting growth opportunities driven by medical advancements and innovative therapies.
New Enterprise Associates
A prominent venture capital firm established in 1977, dedicated to partnering with entrepreneurs to build transformative businesses across various sectors.
What's next for Polyneuron Pharmaceuticals?
With the successful completion of its recent financing, Polyneuron Pharmaceuticals is poised to advance its clinical development programs with increased velocity. The strategic focus will likely remain on the progression of PN-1007 through clinical milestones, while simultaneously exploring the scalability of the Antibody-Catch platform for broader therapeutic applications. As the company matures, the emphasis will shift toward establishing robust commercialization pathways and potential strategic partnerships to maximize the impact of its glycopolymer-based interventions. Investors will be closely monitoring the upcoming clinical data readouts, which will serve as a critical catalyst for the company's long-term valuation and market penetration strategy.
See full Polyneuron Pharmaceuticals company page
